Cargando…

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer

BACKGROUND: To explore potential metabolomics biomarker in predicting the efficiency of the chemo-immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 83 eligible patients were assigned to receive chemo-immunotherapy. Serum samples were prospectively collec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Lihong, Zhang, Zhihua, Li, Xushuo, Yang, Ying, Qi, Ruixue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887290/ https://www.ncbi.nlm.nih.gov/pubmed/36733356 http://dx.doi.org/10.3389/fonc.2022.1025046

Ejemplares similares

Metabolomics profiling in predicting of post-herpetic neuralgia induced by varicella zoster
por: Lu, Lina, et al.
Publicado: (2023)

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
por: Zhao, Shuang, et al.
Publicado: (2021)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer
por: He, Kewen, et al.
Publicado: (2022)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hellwig, Konstantin, et al.
Publicado: (2021)

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study
por: Dai, Wangshu, et al.
Publicado: (2021)

Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer via Computed Tomography Derived Radiomic Features
por: Liu, Yixin, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
por: Du, Ping, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
por: Kaplon, Hélène
Publicado: (2022)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
por: Hu, Chen, et al.
Publicado: (2021)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
por: Yang, Hongjian, et al.
Publicado: (2023)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

The modulation of ion channels in cancer chemo-resistance
por: Zhao, Jiayu, et al.
Publicado: (2022)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside
por: Montoya, Chris, et al.
Publicado: (2023)

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis
por: Wang, Min, et al.
Publicado: (2015)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023)

Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy
por: Dastmalchi, Farhad, et al.
Publicado: (2021)

Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
por: Xiang, Jiajia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_405bvpcraoja677digctr1vqqm